The SELECT trial was the first major outcomes study to demonstrate that a GLP-1 medication reduces cardiovascular events in adults with overweight or obesity who do not have diabetes. Published in the New England Journal of Medicine in November 2023, it changed how the field thinks about semaglutide. Before SELECT, the cardiovascular benefit of GLP-1s was well-established in patients with diabetes (through trials like LEADER, SUSTAIN-6, and SOUL). SELECT extended the benefit to a much larger population: the roughly 110 million American adults with overweight or obesity, the majority of whom do not have a diabetes diagnosis.

The headline result was a 20 percent reduction in the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. The subtler and arguably more interesting finding was that the benefit appeared to be only partly mediated by weight loss. That detail has shaped how clinicians, regulators, and payers think about semaglutide's role in cardiovascular prevention.

What SELECT was designed to answer

The trial enrolled 17,604 adults across 41 countries who met three criteria: age 45 or older, body mass index 27 or higher, and established cardiovascular disease (prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease). Patients with diabetes were excluded. Participants were randomized 1:1 to once-weekly semaglutide 2.4 mg subcutaneous injection (the obesity dose, identical to Wegovy) or matching placebo, on top of standard care for cardiovascular risk factors.

The primary endpoint was the time to first occurrence of major adverse cardiovascular events (MACE), defined as the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Mean follow-up was 33 months; the longest follow-up exceeded 5 years.

The trial was designed as a superiority trial; semaglutide had to outperform placebo on the primary endpoint to declare a positive result. The sample size was powered to detect a relative risk reduction of approximately 17 percent or greater with 90 percent power.

The primary outcome

MACE occurred in 6.5 percent of the semaglutide group and 8.0 percent of the placebo group. The hazard ratio was 0.80 (95% confidence interval 0.72 to 0.90), with a p-value of less than 0.001. In absolute terms, treating 1,000 patients for an average of 33 months with semaglutide prevented approximately 15 first MACE events compared to placebo.

The 20 percent relative risk reduction is similar in magnitude to what's seen with statins for secondary cardiovascular prevention, and it's on par with the GLP-1 outcomes trials in diabetes (LEADER showed 13 percent for liraglutide; SUSTAIN-6 showed 26 percent for semaglutide at lower obesity doses; SOUL showed 14 percent for oral semaglutide).

Component breakdown

The individual components of the composite endpoint all moved in the same direction, with the largest signal coming from nonfatal myocardial infarction:

Timing of the cardiovascular benefit

One of the more striking findings was how quickly the MACE curves separated. The semaglutide and placebo curves began to diverge within three months of randomization, well before substantial weight loss had occurred in the semaglutide group. By six months, the curves were clearly separated. By two years, the separation was robust.

The implication is that semaglutide's cardiovascular benefit is not purely a downstream consequence of weight loss. Weight loss takes time; the divergence at three months suggests that other mechanisms are contributing. The candidates include direct anti-inflammatory effects (semaglutide reduces high-sensitivity C-reactive protein), modest blood pressure reduction, lipid effects, improvements in endothelial function, and direct effects on myocardial and vascular tissue.

The weight-independence analysis

The 2025 prespecified Lancet analysis examined whether the MACE benefit was mediated by weight loss. The authors found that the hazard ratio for MACE remained meaningfully reduced (HR approximately 0.85) even after statistical adjustment for changes in body weight and waist circumference. Roughly one-third of the cardiovascular benefit appeared to be mediated by waist circumference reduction, with the remainder attributed to other mechanisms.

This is clinically important because it suggests semaglutide may be useful for cardiovascular prevention in patients who achieve only modest weight loss. The benefit is not gated on hitting a 15 percent weight reduction target.

Subgroup analyses

Heart failure

A 2024 Lancet subgroup analysis examined the approximately 4,300 SELECT participants with prevalent heart failure. The MACE benefit was even larger in this subgroup, with a hazard ratio of approximately 0.72. This is consistent with the STEP-HFpEF data showing semaglutide improves heart failure outcomes in adults with obesity and HFpEF.

Prior coronary artery bypass grafting

A JACC subgroup analysis examined patients with prior CABG. The MACE benefit was preserved in this subgroup despite their already-aggressive secondary prevention. The hazard ratio in CABG patients was approximately 0.79, comparable to the overall trial.

HbA1c subgroup

SELECT excluded patients with diabetes (HbA1c above 6.5 percent) but enrolled a wide range of glycemic statuses below that threshold. A Diabetes Care subgroup analysis found that the MACE benefit was consistent across HbA1c categories, including patients with prediabetes (HbA1c 5.7 to 6.4 percent) and patients with normal glycemia (HbA1c below 5.7 percent). The benefit was not driven by patients near the diabetes threshold; it extended throughout the cardiometabolic spectrum.

Baseline weight

Patients with higher and lower baseline BMI both showed cardiovascular benefit. The hazard ratios were similar across BMI categories from 27 (overweight) up through severe obesity. This is consistent with the weight-independent mechanism hypothesis.

Sex and age

The cardiovascular benefit was consistent across sex and age subgroups. Women, men, and patients across the 45 to 80 age range showed similar relative risk reductions.

The FDA approval and clinical practice implications

In March 2024, the FDA approved semaglutide 2.4 mg (Wegovy) for cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease. This was the first FDA-approved cardiovascular indication for a GLP-1 medication in a non-diabetic population. The approval was based primarily on the SELECT trial results.

The clinical implication is meaningful. Adults with overweight or obesity and established CVD now have an evidence-supported indication for semaglutide that doesn't depend on weight loss as the primary goal. This shifts the conversation about who should be considered for GLP-1 therapy. The Centers for Medicare and Medicaid Services followed in 2024 with a coverage determination that allows Medicare Part D coverage of Wegovy for the cardiovascular indication.

How this changes prescribing

Limitations of SELECT

Selected population

SELECT enrolled adults with overweight or obesity and established CVD. The results don't directly inform whether GLP-1s benefit cardiovascular outcomes in patients without prior CVD events (primary prevention). The ongoing SCORE real-world study and the various trials in different populations are filling in this picture.

Diabetes excluded

The trial excluded diabetes, by design. The cardiovascular benefits in diabetes are established through separate trial programs (LEADER, SUSTAIN-6, SOUL, REWIND). The SELECT data adds to the picture for non-diabetic populations but does not change the diabetes evidence base.

5-year horizon

The longest follow-up exceeded five years but the trial was not designed to assess very long-term outcomes. Patient compliance, side effect management over multi-year horizons, and rare event rates beyond five years are areas of continued data collection through post-marketing surveillance and registry studies.

Cost-effectiveness

SELECT did not include a formal cost-effectiveness analysis. Subsequent modeling studies have produced varying estimates depending on assumptions about long-term adherence, discount rates, and which costs are included. The cost-effectiveness picture continues to evolve as cash-pay options and manufacturer programs change the effective price patients pay.

Frequently asked questions

Should anyone with overweight or obesity be considered for semaglutide based on SELECT? SELECT specifically enrolled patients with established cardiovascular disease. The strongest evidence applies to that population. Patients with overweight or obesity and other risk factors (hypertension, hyperlipidemia, prediabetes) may benefit from a cardiovascular risk-modifying treatment approach, but the SELECT-level outcome evidence is specific to those with prior CVD events.

Does the cardiovascular benefit apply to tirzepatide? Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing in adults with diabetes. The obesity cardiovascular outcomes trial for tirzepatide (SURMOUNT-MMO) is also ongoing. As of 2026, the SELECT-level evidence is specific to semaglutide. The pharmacology of tirzepatide (dual GLP-1 and GIP agonism) suggests cardiovascular benefit is plausible but not yet demonstrated at the same level of evidence.

Does compounded semaglutide provide the same cardiovascular benefit? The cardiovascular benefit observed in SELECT was driven by semaglutide's pharmacological action at the GLP-1 receptor. Compounded semaglutide prepared by a state-licensed 503A pharmacy contains the same active pharmaceutical ingredient when prepared properly. The clinical implication is that compounded semaglutide with proper dosing and adherence is generally expected to provide similar pharmacological effects, though no head-to-head outcomes trial of compounded versus branded semaglutide has been conducted.

Is the 20 percent MACE reduction clinically meaningful? Yes. A 20 percent relative reduction in the composite of cardiovascular death, nonfatal MI, and nonfatal stroke is comparable to the benefit of statin therapy in secondary prevention and exceeds the benefit of many widely used cardiovascular medications. The number needed to treat to prevent one MACE event over 33 months in the SELECT population was approximately 67.

Will SELECT change how Medicare and commercial insurance cover semaglutide? It already has. CMS issued a 2024 coverage determination allowing Medicare Part D coverage of Wegovy for the cardiovascular indication. Commercial coverage of semaglutide for the CV indication has expanded since 2024, though many plans still require prior authorization documenting the cardiovascular indication.

The Bottom Line

SELECT established that semaglutide 2.4 mg reduces cardiovascular events by approximately 20 percent in adults with overweight or obesity and established cardiovascular disease, with benefit appearing within three months and being only partly explained by weight loss. The trial led to the first FDA-approved cardiovascular indication for a GLP-1 in a non-diabetic population and has shifted how clinicians, regulators, and payers think about the role of GLP-1s in cardiovascular prevention. The evidence is specific to semaglutide 2.4 mg; tirzepatide cardiovascular outcomes data is still in progress.

CLYR Health offers compounded semaglutide for eligible adults with physician supervision. Licensed providers, transparent flat-rate pricing, 503A pharmacy fulfillment. Start your assessment at /intake.html.